Search

Your search keyword '"Overton, Timothy G."' showing total 17 results
Start Over Author "Overton, Timothy G." Publication Year Range Last 50 years
17 results on '"Overton, Timothy G."'

4. Postponing Early intrauterine Transfusion with Intravenous immunoglobulin Treatment; the PETIT study on severe hemolytic disease of the fetus and newborn

Author

Zwiers, Carolien, van der Bom, Johanna G., van Kamp, Inge L., van Geloven, Nan, Lopriore, Enrico, Smoleniec, John, Devlieger, Roland, Sim, Pauline E., Ledingham, Marie Anne, Tiblad, Eleonor, Moise, Kenneth J., Jr., Gloning, Karl-Philip, Kilby, Mark D., Overton, Timothy G., Jørgensen, Ditte S., Schou, Katrine V., Paek, Bettina, Walker, Martin, Parry, Emma, Oepkes, Dick, and de Haas, Masja

Published
2018
Full Text
View/download PDF

13. Prenatal diagnosis by minimally invasive first-trimester transcervical sampling is unreliable

Author

Overton, Timothy G., Lighten, Antony D., Fisk, Nicholas M., and Bennett, Phillip R.

Subjects
Polymerase chain reaction, Pregnant women, Fluorescence, Cytogenetics, Nucleic acids, Health
Abstract

Byline: Timothy G. Overton, Antony D. Lighten, Nicholas M. Fisk, Phillip R. Bennett Keywords: Fetal cells; transcervical; polymerase chain reaction; fluorescence in situ hybridization; prenatal diagnosis Abstract: OBJECTIVE: We investigated whether reliable prenatal diagnosis is possible from fetal cells harvested transcervically in first-trimester pregnancies. STUDY DESIGN: Fetal cells were obtained transcervically from 87 women undergoing pregnancy termination. Fetal gender was determined in 51 pregnancies with three different polymerase chain reaction techniques and in 36 pregnancies with fluorescent in situ hybridization. In known male pregnancies the number of male fetal cells present was also determined. RESULTS: Polymerase chain reaction detected male deoxyribonucleic acid in up to 79% of cases in male pregnancies and up to 45% of cases in female pregnancies. Fetal gender was correctly predicted in up to 72% of cases with fluorescent in situ hybridization. However, fetal cells were identified in Author Affiliation: London, United Kingdom Article History: Received 3 October 1995; Revised 2 November 1995; Accepted 29 January 1996 Article Note: (footnote) [star] From the Royal Postgraduate Medical School, Institute of Obstetrics and Gynaecology, Queen Charlotte's and Chelsea Hospital., [star][star] Supported by grants from Action Research., a Reprint requests: T.G. Overton, MB, BS, Royal Postgraduate Medical School, Institute of Obstetrics and Gynaecology, Queen Charlotte's and Chelsea Hospital, Goldhawk Road, London, United Kingdom W6 OXG., aa 0002-9378/96 $5.00 + 0 6/1/72364

Published
1996

14. Accuracy of prenatal determination of RhD type status by polymerase chain reaction with amniotic cells

Author

Lighten, Antony D., Overton, Timothy G., Sepulveda, Waldo, Warwick, Ruth M., Fisk, Nicholas M., and Bennett, Phillip R.

Subjects
Erythroblastosis fetalis -- Diagnosis, Polymerase chain reaction, Amniocentesis, Health
Abstract

The RhD blood type of fetuses may be determined early in pregnancy through the analysis of amniotic fluid without sensitizing the mothers' blood to the fetus's different blood type. Such analysis may enable doctors to know whether or not to treat the mother with anti-D immunoglobulin to prevent sensitization of the mother's blood and poor outcomes for the fetus. Researchers performed amniocentesis on 95 pregnant women whose blood was RhD negative and where the father's blood was RhD positive. Amniotic fluid was analyzed for fetal RhD type by polymerase chain reaction and the results were compared to either fetal blood samples or to samples of umbilical cord blood after birth. Thirty-six fetuses were correctly typed as RhD negative, and 96 of 98 fetuses were correctly typed as RhD positive.

Published
1995

17. Non-Invasive Screening Tools for Down's Syndrome: A Review.

Author

Sillence, Kelly A., Madgett, Tracey E., Roberts, Llinos A., Overton, Timothy G., and Avent, Neil D.

Subjects
DOWN syndrome, PRENATAL diagnosis, DEVELOPMENTAL delay, DIAGNOSIS of fetal diseases, DIAGNOSIS
Abstract

Down's syndrome (DS) is the most common genetic cause of developmental delay with an incidence of 1 in 800 live births, and is the predominant reason why women choose to undergo invasive prenatal diagnosis. However, as invasive tests are associated with around a 1% risk of miscarriage new non-invasive tests have been long sought after. Recently, the most promising approach for non-invasive prenatal diagnosis (NIPD) has been provided by the introduction of next generation sequencing (NGS) technologies. The clinical application of NIPD for DS detection is not yet applicable, as large scale validation studies in low-risk pregnancies need to be completed. Currently, prenatal screening is still the first line test for the detection of fetal aneuploidy. Screening cannot diagnose DS, but developing a more advanced screening program can help to improve detection rates, and therefore reduce the number of women offered invasive tests. This article describes how the prenatal screening program has developed since the introduction of maternal age as the original "screening" test, and subsequently discusses recent advances in detecting new screening markers with reference to both proteomic and bioinformatic techniques. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results